NASDAQ$TELA

TELA Bio Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Reported a solid quarter driven by strong demand for soft-tissue reconstruction solutions.

TELA Bio reported a 40% increase in revenue to $8.2 million for the first quarter of 2022. Gross profit reached $5.0 million, representing 61% of revenue. The company's net loss was $10.9 million, and cash and cash equivalents totaled $33.0 million.

  • Revenue increased by 40% compared to the prior year, reaching $8.2 million.
  • Gross profit was $5.0 million, or 61% of revenue, compared to $3.5 million, or 59% of revenue, in the same period in 2021.
  • Operating expenses increased to $14.8 million due to higher salaries, employee-related expenses, travel expenses, and professional fees.
  • Cash and cash equivalents totaled $33.0 million as of March 31, 2022.

Headline financials

Total Revenue

$8.23M

Previous: $5.88M+40.1%
EPS (adj)

-$0.75

Previous: -$0.56-33.9%
Capital Expenditures

-$336K

Previous: -$22K-1427.3%
Free Cash Flow

-$11.2M

Previous: -$8.16M-37.3%
Net Income

-$10.9M

Previous: -$8.14M-33.5%
Operating Income

-$9.84M

Previous: -$7.27M-35.4%
Gross Profit

$5M

Previous: $3.47M+44.3%
Cash & Equivalents

$33M

Previous: $65.8M-49.8%
Total Assets

$55.4M

Previous: $78.3M-29.3%
Stock-Based Comp

$901K

Previous: $694K+29.8%

Revenue & EPS history

TELA Bio · Revenue · Quarterly

$8.23M

Q1 2022+40.1%vs Q1 2021
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Forward guidance

Full year 2022 revenue remains projected to range from $40 million to $45 million, reflecting growth of 36% to 53% over full year 2021.

Headwinds

  • A higher than expected impact from the COVID-19 pandemic in 2022 could materially affect this projection.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

-2.5%

Avg return

Earnings day

-3.7%

Avg return

5 days after

+3.7%

Avg return

30 days after

42%

11 / 26 earnings

Positive

+20.2%

Q1 2024

Best reaction

-37.2%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.3%-18.6%
Q4 2025+1.7%-25.8%-12.0%
Q3 2025-9.3%-2.7%+3.6%
Q1 2025+7.2%-0.1%+90.7%
Q4 2024-37.2%-44.9%-59.1%
Q3 2024+2.0%+3.0%-1.7%
Q2 2024-23.9%-23.4%-35.0%
Q1 2024+20.2%+21.2%+16.7%
Q4 2023+4.0%+0.9%-13.8%
Q3 2023-20.3%-21.7%-4.5%
Q2 2023-4.8%-1.2%-2.8%
Q1 2023-3.6%-4.8%+11.2%
Q4 2022-5.5%-3.7%-11.3%
Q3 2022+13.8%+11.2%+44.7%
Q2 2022-6.5%+5.5%+0.9%
Q1 2022-5.7%-7.0%-31.4%
Q4 2021-4.8%-4.8%-20.4%
Q3 2021-3.8%-3.7%-1.7%
Q2 2021+5.0%+4.4%-8.3%
Q1 2021+3.2%+11.5%+5.9%
Q4 2020-6.6%+0.9%-1.8%
Q3 2020-3.5%-0.8%-3.6%
Q2 2020+5.4%+4.1%+20.7%
Q1 2020-2.4%-3.6%+38.6%
Q4 2019+0.6%-0.4%+34.0%
Q3 2019+13.9%+8.8%+32.6%
Q2 2019
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro